A recent study published in Nature Medicine indicates that a single dose of psilocybin, the active compound in magic mushrooms, can provide significant relief for patients suffering from depression that has not responded to previous treatments. This marks the first time a publicly-funded clinical trial has tested this psychedelic therapy for treatment-resistant cases.
The trial, conducted by King’s College London at the South London and Maudsley NHS Foundation Trust, monitored 60 participants. Half received a 25mg dose of psilocybin while the other half received a placebo. Both groups received psychological support throughout the process. The results show that 43 percent of those who received the psychedelic treatment reached the threshold for a positive response after three weeks, with that number increasing to 56 percent by the six-week mark. Only 3 percent of the placebo group saw similar results.
Researchers also noted that 40 percent of participants in the psilocybin group entered remission, where their symptoms dropped below the diagnostic threshold for depression. This remission remained consistent at the six-week follow-up, whereas the placebo group saw only a 3 percent remission rate.
Participants reported that the experience was intense and emotional, with some patients describing it as a difficult but necessary process that allowed them to better understand their mental health. One patient noted that the therapy helped them confront grief, stating that the challenging nature of the session felt like a necessary part of their recovery.
Lead researchers highlighted that the study was conducted successfully in a community mental health building rather than a standard hospital ward. This suggests that with proper support and training, this therapy could be safely administered in less clinical settings, potentially reducing patient anxiety. The team plans to use these findings to advocate for larger, publicly funded trials to further validate psilocybin as a viable medical intervention.